Supplementary table 3 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
Richard P. Tobin(Society of Surgical Oncology), Martin D. McCarter(University of Colorado Cancer Center), Karl D. Lewis(University of Colorado Denver), Jessica S.W. Borgers(The Netherlands Cancer Institute), Kimberly R. Jordan(University of Colorado Anschutz Medical Campus), Theresa Medina(University of Colorado Cancer Center), Elizabeth Katsnelson(University of Colorado Anschutz Medical Campus), William A. Robinson(University of Colorado Anschutz Medical Campus), Kasey L. Couts(University of Colorado Anschutz Medical Campus), Victoria M. Cates(University of Colorado Anschutz Medical Campus), Dexiang Gao(University of Colorado Cancer Center), Eduardo Davila(University of Colorado Cancer Center), Robert J. Van Gulick(University of Colorado Anschutz Medical Campus), Dana M. Davis(Dalhousie University), René González(University of Miami), Ross W. McFarland(Cancer Clinic), Dasha T. Cogswell(University of Colorado Anschutz Medical Campus)
Cited by 0
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k